Vertex acquired Exonics a private entity focused on CRISPR Cas9 editing. They received funding from Cureduchennes which appears to have led to the Vertex decision to buy the IP and program from CRSP to pursue internally with Exonics editing.
Appears the 3 addl targets that were triggered by Vertex were CF, DMD, DM1 leaving only CF now that Vertex is taking the other two internal. Not sure why the small difference in milestone potential though. $410 per program vs $825 for these two. So 6 targets became 3 though CRSP gets paid handsomely for DMD and DM1 if successful and has an option to participate by paying for 1/2 dev and co-commercialize.